About FDA

Office of Global Regulatory Operations and Policy (GO)

Effective March 31, 2019, FDA will begin operational implementation of an agency reorganization. FDA’s reorganization reflects the agency’s commitment to modernizing its structure to advance its mission to protect and promote public health, and to meet the challenges of rapid innovation across the industries regulated by FDA. The FDA’s reorganization will realign several entities across the agency to promote strategic priorities, and will elevate the role of the centers, offices and field forces.

This organization chart reflects the new structure under which FDA will operate.

FDA Globalization- Offices in China, Europe, Latin America, and IndiaThe Office of Global Regulatory Operations and Policy (also known as GO) comprises the Office of Regulatory Affairs and the Office of International Programs. The Deputy Commissioner for GO provides executive oversight, strategic leadership, and policy direction to FDA’s domestic and international product quality and safety efforts, including global collaboration, global data-sharing, development and harmonization of standards, field operations, compliance, and enforcement activities. A fuller explanation of FDA Globalization initiatives can be found on the International Programs - Globalization page


A New World for Pharmaceutical Inspections- The Mutual Recognition Agreement

Please click here for Information on the Mutual Recognition Agreement

Presentations

Contact FDA

 
Office of Global Regulatory Operations and Policy

10903 New Hampshire Avenue

Building 1

Silver Spring, MD 20993

Page Last Updated: 03/21/2019
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English